GB9918180D0 - Novel compositions - Google Patents

Novel compositions

Info

Publication number
GB9918180D0
GB9918180D0 GBGB9918180.2A GB9918180A GB9918180D0 GB 9918180 D0 GB9918180 D0 GB 9918180D0 GB 9918180 A GB9918180 A GB 9918180A GB 9918180 D0 GB9918180 D0 GB 9918180D0
Authority
GB
United Kingdom
Prior art keywords
novel compositions
compositions
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9918180.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9918180.2A priority Critical patent/GB9918180D0/en
Publication of GB9918180D0 publication Critical patent/GB9918180D0/en
Priority to EP00958343A priority patent/EP1200415A1/en
Priority to PCT/EP2000/007423 priority patent/WO2001009106A1/en
Priority to JP2001514309A priority patent/JP2003506362A/en
Priority to AU69898/00A priority patent/AU6989800A/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB9918180.2A 1999-08-02 1999-08-02 Novel compositions Ceased GB9918180D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9918180.2A GB9918180D0 (en) 1999-08-02 1999-08-02 Novel compositions
EP00958343A EP1200415A1 (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic acid derivatives as gsk-3 inhibitors
PCT/EP2000/007423 WO2001009106A1 (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
JP2001514309A JP2003506362A (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic acid derivatives as GSK-3 inhibitors
AU69898/00A AU6989800A (en) 1999-08-02 2000-07-31 Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918180.2A GB9918180D0 (en) 1999-08-02 1999-08-02 Novel compositions

Publications (1)

Publication Number Publication Date
GB9918180D0 true GB9918180D0 (en) 1999-10-06

Family

ID=10858425

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9918180.2A Ceased GB9918180D0 (en) 1999-08-02 1999-08-02 Novel compositions

Country Status (5)

Country Link
EP (1) EP1200415A1 (en)
JP (1) JP2003506362A (en)
AU (1) AU6989800A (en)
GB (1) GB9918180D0 (en)
WO (1) WO2001009106A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (en) * 2000-05-11 2003-09-16 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES
PL209780B1 (en) 2000-05-11 2011-10-31 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk−3
EP1712550A3 (en) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
PT1355889E (en) * 2000-12-22 2006-09-29 Ortho Mcneil Pharm Inc SUBSTITUTED DIAMINE TRIAZOLE DERIVATIVES AS KINASE INHIBITORS
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
CA2455753A1 (en) * 2001-08-03 2003-02-13 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
JP2008514645A (en) 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー CAI-based systems and methods for the topical treatment of eye diseases and other diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
WO2006042215A1 (en) 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009507080A (en) * 2005-09-07 2009-02-19 リゲル ファーマシューティカルズ,インコーポレーテッド Triazole derivatives useful as Axl inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008083354A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
PL2078010T3 (en) 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2656496T3 (en) 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as AXL inhibitors
ES2424259T3 (en) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoles substituted with polycyclic aryl and polycyclic heteroaryl, useful as inhibitors of Axl
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2328888B1 (en) 2008-07-09 2012-11-07 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US8546433B2 (en) 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
WO2024218236A1 (en) * 2023-04-18 2024-10-24 Centre National De La Recherche Scientifique 3,5-diaminotriazole derivatives and uses thereof for treating ocular diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
FI850994L (en) * 1984-03-16 1985-09-17 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA 1,2,4-TRIAZACYKLOALKADIENDERIVAT.
DE69917296T2 (en) * 1998-08-20 2005-05-25 Smithkline Beecham Corp. NEW SUBSTITUTED TRIAZONE COMPOUNDS

Also Published As

Publication number Publication date
WO2001009106A1 (en) 2001-02-08
AU6989800A (en) 2001-02-19
JP2003506362A (en) 2003-02-18
EP1200415A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
HU0303215D0 (en) Novel composition
GB9918180D0 (en) Novel compositions
HUP0202826A3 (en) Novel composition
GB9921037D0 (en) Compositions
GB9904049D0 (en) Rapidly-soluble compositions
GB9902520D0 (en) Composition
AP2001002273A0 (en) Rescorcinol composition
GB2366984B (en) Composition
GB9920148D0 (en) Novel composition
GB9914446D0 (en) Composition
GB9929622D0 (en) Compositions
GB9903924D0 (en) Cosmectic compositions
GB9904931D0 (en) Compositions
GB9926833D0 (en) Compositions
GB0029300D0 (en) Composition
GB0029455D0 (en) Novel compositions
GB9914582D0 (en) Composition
GB9912423D0 (en) Compositions
GB9912420D0 (en) Compositions
GB9905571D0 (en) Compositions
GB9912422D0 (en) Compositions
GB9904599D0 (en) Compositions
GB9905572D0 (en) Compositions
GB9904057D0 (en) Compositions
GB9912421D0 (en) Compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)